Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral BCG in advanced cutaneous melanoma
IRCT20251104067875N1Phase 2Recruiting
- Sponsor
- Shahid Beheshti University of Medical Sciences
- Start
- Sep 2025
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of PastoCys in cutaneous melanoma (CM), sponsored by Shahid Beheshti University of Medical Sciences. Primary endpoints: disease-free survival and overall survival. Started Sep 2025; status: recruiting.
02
Drugs
PastoCys
03
Conditions
cutaneous melanoma (CM)
Beyond the preview
Go deeper on IRCT20251104067875N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20251104067875N1.